Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, efficacy and PK of IdeS in kidney transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Kidney Disease

Drugs mentioned

• IdeS (Immunoglobulin-degrading enzyme of Streptococcus pyogenes)

Snippet

Sponsor: Hansa Biopharma AB | Conditions: End Stage Kidney Disease | Phase 2 | Status: COMPLETED